CCM
NVO

Coldstream Capital Management’s Novo Nordisk NVO Stock Holding History

Coldstream Capital Management’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.11M Buy
44,005
+663
+2% +$28.5K 0.03% 296
2026
Q1 		$1.59M Buy
43,342
+645
+2% +$30.6K 0.02% 353
2025
Q4 		$2.17M Sell
42,697
-2,476
-5% -$127K 0.03% 266
2025
Q3 		$2.51M Sell
45,173
-13,372
-23% -$783K 0.03% 243
2025
Q2 		$4.04M Buy
58,545
+6,828
+13% +$464K 0.07% 165
2025
Q1 		$3.59M Buy
51,717
+31,000
+150% +$2.56M 0.08% 153
2024
Q4 		$1.78M Sell
20,717
-1,647
-7% -$178K 0.04% 264
2024
Q3 		$2.66M Buy
22,364
+1,831
+9% +$244K 0.06% 190
2024
Q2 		$2.93M Sell
20,533
-287
-1% -$38K 0.07% 144
2024
Q1 		$2.67M Buy
20,820
+4,224
+25% +$503K 0.07% 149
2023
Q4 		$1.72M Buy
16,596
+6,914
+71% +$684K 0.05% 202
2023
Q3 		$880K Sell
9,682
-50
-0.5% -$4.41K 0.03% 285
2023
Q2 		$787K Sell
9,732
-596
-6% -$48.7K 0.02% 315
2023
Q1 		$822K Buy
10,328
+598
+6% +$42.4K 0.03% 307
2022
Q4 		$658K Buy
+9,730
New +$570K 0.02% 350
2022
Q2 		$607K Buy
+10,906
New +$605K 0.02% 338
2022
Q1 		– Sell
-8,374
Closed -$469K – 836
2021
Q4 		$469K Buy
+8,374
New +$454K 0.01% 445
2016
Q2 		– Sell
-19,280
Closed -$522K – 247
2016
Q1 		$522K Buy
+19,280
New +$517K 0.1% 117
2015
Q1 		– Sell
-19,466
Closed -$412K – 161
2014
Q4 		$412K Buy
19,466
+76
+0.4% +$1.7K 0.11% 104
2014
Q3 		$462K Sell
19,390
-5,630
-23% -$130K 0.13% 97
2014
Q2 		$578K Buy
25,020
+10
+0% +$221 0.17% 88
2014
Q1 		$571K Hold
25,010
– – 0.18% 84
2013
Q4 		$462K Buy
25,010
+5,600
+29% +$97.6K 0.15% 95
2013
Q3 		$328K Buy
19,410
+270
+1% +$4.54K 0.11% 112
2013
Q2 		$297K Buy
+19,140
New +$319K 0.1% 123

Other funds holding NVO

Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Coldstream Capital Management's NVO Position: Q2 2026 in Review

Coldstream Capital Management increased its Novo Nordisk (NVO) stake by 1.5% in Q2 2026, buying an estimated $28.5K and bringing the position to 44,005 shares worth $2.11M. The position accounts for 0.03% of the portfolio, ranked #296.

Coldstream Capital Management first reported a position in NVO in Q2 2013 and has held it in 25 quarters since. The position peaked at $4.04M in Q2 2025. 1,356 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • Coldstream Capital Management held 44,005 shares of Novo Nordisk worth $2.11M as of Q2 2026.
  • Coldstream Capital Management bought 663 Novo Nordisk shares in Q2 2026, an estimated $28.5K.
  • Novo Nordisk made up 0.03% of Coldstream Capital Management's portfolio in Q2 2026, its #296 holding.
  • Coldstream Capital Management first reported a position in Novo Nordisk in Q2 2013 and has held it in 25 quarters since.
  • Coldstream Capital Management's Novo Nordisk position peaked at $4.04M in Q2 2025.
  • 1,356 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Coldstream Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.